1. SNMMI. Targeted cancer treatment with nuclear medicine therapy. (http://s3.amazonaws.com/rdcms-snmmi/files/production/public/images/2020%20TRT%20Infographic%20%281%29.pdf).
2. Highlights of prescribing information: LUTATHERA (lutetium Lu-177 dotatate) injection, for intravenous use. (https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208700s000lbl.pdf).
3. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment;Sandstrom;J Nucl Med,2013
4. Phase 3 trial of (177)lu-dotatate for midgut neuroendocrine tumors;Strosberg;N Engl J Med,2017
5. Highlights of prescribing information: AZEDRA (iobenguane I-131) injection, for intravenous use. (https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209607s000lbl.pdf).